Visit Patient Landing Page

You are now leaving our website.

If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party that is solely responsible for its content. Amgen provides this link as a service to website visitors. Amgen is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Continue Cancel
global-banner-bg
global-banner-bg-sm

Most ASCVD patients are at very high risk for an MI or stroke1

Identifying your patients’ risk status

Patients are defined as being at very high risk for CV events based on the following factors2

patients-risk-status
patients-risk-status-sm
Stopwatch

The rate of recurrent CV events in at-risk patients is highest within the 1st year of a prior event3

Very high-risk patients with ASCVD are more likely to have a CV event than those with ASCVD not at very high risk4

CV event rates based on patient risk status

even-rate-per-100-patient-years

Retrospective cohort study analyzed data from US adults included in the Prognos LDL-C database from January 1, 2011 to June 30, 2018. Patients were ≥ 18 years old and had ≥ 2 nonancillary medical claims in the linked databases at least 30 days apart. The study was conducted in two stages: 1) identification of patients with ASCVD who met the definition of very high-risk ASCVD and a matched cohort of non–very high-risk ASCVD patients using the incidence density sampling approach; 2) estimation of the occurrence of major CV events.

IS = ischemic stroke; MI = myocardial infarction; UA = unstable angina hospitalization.

In the prospective, observational GOULD registry (N = 5,006)5

only-15-percent

OF PATIENTS rECEIVING LIPID-LOWERING THERAPIES ACHIEVED LDL-C < 55 mg/dL

See LDL-C TEsting recommendations

GOULD is a prospective, observational registry study tracking lipid-lowering therapies for patients with ASCVD over a two-year period.

References: 1. Muntner P, Orroth KK, Mues KE, et al. Evaluating a simple approach to identify adults meeting the 2018 AHA/ACC cholesterol guideline definition of very high risk for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2022;36:475-481. 2. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418. 3. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-1357. 4. Fonarow GC, Kosiborod MN, Rane PB, et al. Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease. Clin Cardiol. 2021;44:1457-1466. 5. Cannon CP, de Lemos JA, Rosenson RS, et al; for the GOULD Investigators. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6:1060-1068.